Multi-scaled transcriptomics of chronically inflamed nasal epithelium reveals immune-epithelial dynamics and tissue remodeling in nasal polyp formation
- PMID: 40945518
- DOI: 10.1016/j.immuni.2025.08.009
Multi-scaled transcriptomics of chronically inflamed nasal epithelium reveals immune-epithelial dynamics and tissue remodeling in nasal polyp formation
Abstract
Chronic rhinosinusitis (CRS) is a common chronic inflammatory disease of the sinonasal cavity affecting millions worldwide. Its complex pathophysiology remains poorly understood, with emerging evidence implicating interactions between diverse immune and epithelial cells in disease progression. We applied single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics to both dissociated and intact human tissues from individuals with CRS with and without nasal polyps and compared them with controls. We revealed mechanisms of macrophage-eosinophil recruitment, CD4+ and CD8+ T cell dysregulation, and mast cell enrichment. We identified key immune-epithelial interactions in tissue remodeling, particularly involving basal progenitor and tuft cells. A distinct basal cell trajectory was implicated in nasal polyp formation. Orthogonal validation with spatial transcriptomics from >100 individuals with CRS revealed conserved tissue remodeling features. Our study provides insights into CRS pathophysiology, highlighting immune-epithelial interactions as potential therapeutic targets in chronic inflammation, also serving as a resource for dissecting immune disease mechanisms.
Keywords: autoimmunity; chronic rhinosinusitis; inflammation; nasal epithelium; nasal polyp; remodeling; single-cell; spatial transcriptomics; type 2 inflammation.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests S.J. is a co-founder of Elucidate Bio Inc. and serves on its Board of Directors and Scientific Advisory Board and acknowledges research support from Sanofi and Roche unrelated to this work. G.N. is co-founder of IonPath Inc and Akoya Biosciences, Inc.; inventor on patent US9909167; and is a Scientific Advisory Board member for Akoya Biosciences, Inc. V.B. has patents on the programmed cell death 1 (PD-1) pathway licensed by Bristol-Myers Squibb, Roche, Merck, EMD Serono, Boehringer Ingelheim, AstraZeneca, Novartis, and Dako unrelated to this work. J.V.N. is a consultant with Sound Health, C2Dx, Aerin Medical, Acclarent/Integra, and SpirAir, all unrelated to this work.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
